Targeted Cancer Therapies Showing Promise in Treating Parenchymal Brain Metastases

Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.

In a recent paper, researchers compiled the most recent evidence on predictive biomarkers for treating parenchymal brain metastases (BM), a common cause of mortality and morbidity in patients, as more data comes to light on which molecular alterations show clinically meaningful efficacy when targeted.

The learnings on treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer (NSCLC), breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.

“Intracranial efficacies were postulated for several next- generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors during the last decades in patients with BM from different solid tumors.

However, targeted- and immuno- therapy were fully efficient only in a selected number of patients underscoring the need for biomarkers to support appropriate selection of individualized treatments and maximize clinical benefits for BM patients,” explained the researchers.

“In addition, although finding of recent studies appeal for performing molecular testing of BM, tissue availability still present a clinical obstacle.”